Why SVRA matters now
Savara Inc. (SVRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.56 with -0.54% on the session and $1.14B in market capitalization; recent performance reads 1-month +16.53% and YTD -8.79%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-37.3M, and EPS of $-0.15. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.5%.
The latest indexable market news headline is "Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.00; recent insider activity includes Lowrance David L filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.91
P/S
0.00
EV/EBITDA
-8.65
DCF Value
$-0.00
FCF Yield
-9.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-87.2%
ROA
-58.4%
ROIC
-65.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-37.3M | $-0.15 |
| Q4 2025 | $0.00 | $-32.2M | $-0.13 |
| FY 2025 | $0.00 | $-118.8M | $-0.53 |
| Q3 2025 | $0.00 | $-29.6M | $-0.14 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.00
Target (Median)
$10.00
Target Range
$10.00 - $10.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.27
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.